This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
• Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
• The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
• The highest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase II. Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, topical, and intravenous formulations.
• High-impact upcoming events for drugs in the systemic hypertension space comprise topline Phase III trial results for firibastat and aprocitentan.
• The overall likelihood of approval of a Phase I systemic hypertension asset is 7%, and the average probability a drug advances from Phase III is 69.6%. Drugs, on average, take 7.3 years from Phase I to approval, compared to 10.2 years in the overall cardiovascular space.
• The distribution of clinical trials across Phase I–IV indicates that a slight majority of trials for hypertension have been in the early and mid-phases of development, with 51% of trials in Phase I–II and 49% in Phase III–IV.
• The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 432 trials. Novartis also leads industry sponsors with by far the highest overall number of
  clinical trials for hypertension.